NASDAQ:CNAT - Conatus Pharmaceuticals News Headlines

Sign in or create an account to add this stock to your watchlist.
$1.52 0.00 (0.00 %)
(As of 12/16/2018 09:39 AM ET)
Previous Close$1.52
Today's Range$1.50 - $1.59
52-Week Range$1.49 - $7.95
Volume878,143 shs
Average Volume1.08 million shs
Market Capitalization$46 million
P/E Ratio-2.49
Dividend YieldN/A
Beta1.99

Headlines

Conatus Pharmaceuticals (NASDAQ CNAT) News Headlines

Source:
DateHeadline
Conatus: Was That Trial A Total Failure?Conatus: Was That Trial A Total Failure?
seekingalpha.com - December 11 at 4:46 PM
Conatus: A Rare Investment For Opportunistic InvestorsConatus: A Rare Investment For Opportunistic Investors
seekingalpha.com - December 11 at 4:46 PM
Conatus And Emricasan In NASH Cirrhotic Portal Hypertension: The Overlooked Therapeutic PromiseConatus And Emricasan In NASH Cirrhotic Portal Hypertension: The Overlooked Therapeutic Promise
seekingalpha.com - December 10 at 9:52 AM
Oppenheimer Research Analysts Cut Earnings Estimates for Conatus Pharmaceuticals Inc (CNAT)Oppenheimer Research Analysts Cut Earnings Estimates for Conatus Pharmaceuticals Inc (CNAT)
www.americanbankingnews.com - December 10 at 1:44 AM
FY2019 Earnings Estimate for Conatus Pharmaceuticals Inc (CNAT) Issued By SunTrust BanksFY2019 Earnings Estimate for Conatus Pharmaceuticals Inc (CNAT) Issued By SunTrust Banks
www.americanbankingnews.com - December 10 at 1:44 AM
Shares of Conatus Pharmaceuticals plummet over 50% after Phase 2 trial fails to meet primary endpoint - MarketWatchShares of Conatus Pharmaceuticals plummet over 50% after Phase 2 trial fails to meet primary endpoint - MarketWatch
www.marketwatch.com - December 8 at 9:16 AM
Conatus Pharmaceuticals (CNAT) PT Lowered to $10 at OppenheimerConatus Pharmaceuticals (CNAT) PT Lowered to $10 at Oppenheimer
www.streetinsider.com - December 7 at 9:08 AM
Why Conatus Pharma Shares Were HalvedWhy Conatus Pharma Shares Were Halved
247wallst.com - December 7 at 9:08 AM
Conatus Emricasan Misses Primary Endpoint in Mid-Stage StudyConatus' Emricasan Misses Primary Endpoint in Mid-Stage Study
finance.yahoo.com - December 7 at 9:08 AM
Conatus Pharmaceuticals (CNAT) PT Lowered to $14 at H.C. WainwrightConatus Pharmaceuticals (CNAT) PT Lowered to $14 at H.C. Wainwright
www.streetinsider.com - December 7 at 9:08 AM
Implied Volatility Surging for Conatus (CNAT) Stock OptionsImplied Volatility Surging for Conatus (CNAT) Stock Options
www.zacks.com - December 7 at 9:08 AM
Conatus May Still Have A Path Forward After Latest Phase 2b DataConatus May Still Have A Path Forward After Latest Phase 2b Data
seekingalpha.com - December 7 at 9:08 AM
U.S. STOCKS ON THE MOVE-Chipmakers, oil stocks, Facebook, industrial stocks - NasdaqU.S. STOCKS ON THE MOVE-Chipmakers, oil stocks, Facebook, industrial stocks - Nasdaq
www.nasdaq.com - December 6 at 4:45 PM
U.S. STOCKS ON THE MOVE-Apple, chipmakers, oil stocks, Boeing, Amazon, Conatus - NasdaqU.S. STOCKS ON THE MOVE-Apple, chipmakers, oil stocks, Boeing, Amazon, Conatus - Nasdaq
www.nasdaq.com - December 6 at 4:45 PM
Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis - GlobeNewswireConatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis - GlobeNewswire
globenewswire.com - December 6 at 4:45 PM
U.S. STOCKS ON THE MOVE-Oil stocks, Facebook, Marvell Technology, Conatus Pharma - NasdaqU.S. STOCKS ON THE MOVE-Oil stocks, Facebook, Marvell Technology, Conatus Pharma - Nasdaq
www.nasdaq.com - December 6 at 4:45 PM
Shares of Conatus Pharmaceuticals plummet over 50% after Phase 2 trial fails to meet primary endpointShares of Conatus Pharmaceuticals plummet over 50% after Phase 2 trial fails to meet primary endpoint
finance.yahoo.com - December 6 at 4:45 PM
Conatus Pharmaceuticals (CNAT) PT Lowered to $12.00 at SunTrust BanksConatus Pharmaceuticals (CNAT) PT Lowered to $12.00 at SunTrust Banks
www.americanbankingnews.com - December 6 at 1:29 PM
Conatus Pharmaceuticals (CNAT) Cut to Hold at Stifel NicolausConatus Pharmaceuticals (CNAT) Cut to Hold at Stifel Nicolaus
www.americanbankingnews.com - December 6 at 1:01 PM
Conatus Pharmas emricasan flunks mid-stage NASH study; shares down 62% premarketConatus Pharma's emricasan flunks mid-stage NASH study; shares down 62% premarket
seekingalpha.com - December 6 at 9:08 AM
Conatus (CNAT) ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis Did Dot Meet Primary EndpointConatus (CNAT) ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis Did Dot Meet Primary Endpoint
www.streetinsider.com - December 6 at 9:08 AM
Todays Research Reports on Trending Tickers: Conatus Pharmaceuticals and ExelixisToday's Research Reports on Trending Tickers: Conatus Pharmaceuticals and Exelixis
finance.yahoo.com - December 6 at 9:08 AM
Conatus Pharmaceuticals (CNAT) Given a $10.00 Price Target at OppenheimerConatus Pharmaceuticals (CNAT) Given a $10.00 Price Target at Oppenheimer
www.americanbankingnews.com - December 6 at 8:09 AM
Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH CirrhosisConatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis
finance.yahoo.com - December 5 at 9:28 AM
Why Is Conatus (CNAT) Up 4.7% Since Last Earnings Report?Why Is Conatus (CNAT) Up 4.7% Since Last Earnings Report?
www.zacks.com - December 3 at 9:36 AM
Conatus Pharmaceuticals Inc (CNAT) Given Consensus Recommendation of "Buy" by BrokeragesConatus Pharmaceuticals Inc (CNAT) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 30 at 9:54 AM
 Brokerages Expect Conatus Pharmaceuticals Inc (CNAT) Will Post Quarterly Sales of $8.51 Million Brokerages Expect Conatus Pharmaceuticals Inc (CNAT) Will Post Quarterly Sales of $8.51 Million
www.americanbankingnews.com - November 29 at 5:49 AM
-$0.14 EPS Expected for Conatus Pharmaceuticals Inc (CNAT) This Quarter-$0.14 EPS Expected for Conatus Pharmaceuticals Inc (CNAT) This Quarter
www.americanbankingnews.com - November 27 at 5:18 AM
When Will Conatus Pharmaceuticals Inc (NASDAQ:CNAT) Become Profitable?When Will Conatus Pharmaceuticals Inc (NASDAQ:CNAT) Become Profitable?
finance.yahoo.com - November 16 at 4:39 PM
Do Options Traders Know Something About Conatus (CNAT) Stock We Don't?Do Options Traders Know Something About Conatus (CNAT) Stock We Don't?
finance.yahoo.com - November 14 at 4:40 PM
Do Options Traders Know Something About Conatus (CNAT) Stock We Dont?Do Options Traders Know Something About Conatus (CNAT) Stock We Don't?
www.zacks.com - November 14 at 8:52 AM
Conatus Pharmaceuticals Announces Presentations and Posters at AASLD Annual MeetingConatus Pharmaceuticals Announces Presentations and Posters at AASLD Annual Meeting
finance.yahoo.com - November 8 at 9:24 AM
Conatus Pharmaceuticals among healthcare gainers; Clearside Biomedical leads the losersConatus Pharmaceuticals among healthcare gainers; Clearside Biomedical leads the losers
seekingalpha.com - November 7 at 9:18 AM
Conatus (CNAT) Q3 Loss In Line, Revenues Lag EstimatesConatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates
finance.yahoo.com - November 2 at 4:43 PM
Edited Transcript of CNAT earnings conference call or presentation 1-Nov-18 8:30pm GMTEdited Transcript of CNAT earnings conference call or presentation 1-Nov-18 8:30pm GMT
finance.yahoo.com - November 2 at 4:43 PM
Conatus' (CNAT) Q3 Loss In Line, Revenues Lag EstimatesConatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates
finance.yahoo.com - November 2 at 4:43 PM
Conatus Pharma Q3 revenues down 20%Conatus Pharma Q3 revenues down 20%
seekingalpha.com - November 2 at 9:57 AM
Conatus Pharmaceuticals (CNAT) CEO Steve Mento on Q3 2018 Results - Earnings Call TranscriptConatus Pharmaceuticals (CNAT) CEO Steve Mento on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 2 at 9:57 AM
Conatus: 3Q Earnings SnapshotConatus: 3Q Earnings Snapshot
finance.yahoo.com - November 2 at 9:57 AM
Conatus Pharmaceuticals (CNAT) Reports Q3 Loss, Misses Revenue EstimatesConatus Pharmaceuticals (CNAT) Reports Q3 Loss, Misses Revenue Estimates
finance.yahoo.com - November 2 at 9:57 AM
Conatus Pharmaceuticals EPS in-line, misses on revenueConatus Pharmaceuticals EPS in-line, misses on revenue
seekingalpha.com - November 1 at 4:44 PM
Conatus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Program UpdatesConatus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Program Updates
finance.yahoo.com - November 1 at 4:44 PM
Conatus Pharmaceuticals to Report Third Quarter 2018 Financial ResultsConatus Pharmaceuticals to Report Third Quarter 2018 Financial Results
finance.yahoo.com - October 25 at 9:10 AM
Conatus Pharmaceuticals: Emricasan And Severe Portal HypertensionConatus Pharmaceuticals: Emricasan And Severe Portal Hypertension
seekingalpha.com - October 24 at 4:36 PM
Conatus And Emricasan: The MomentConatus And Emricasan: The Moment
seekingalpha.com - October 8 at 4:39 PM
Conatus Pharmaceuticals (CNAT) Announces Three Accepted Abstracts for AASLDConatus Pharmaceuticals (CNAT) Announces Three Accepted Abstracts for AASLD
www.streetinsider.com - October 3 at 4:37 PM
Conatus Pharmaceuticals Announces Three Accepted Abstracts for AASLD Annual MeetingConatus Pharmaceuticals Announces Three Accepted Abstracts for AASLD Annual Meeting
finance.yahoo.com - October 2 at 4:37 PM
Conatus Pharmaceuticals, Upcoming Presentations, Analysts Review and TargetConatus Pharmaceuticals, Upcoming Presentations, Analysts Review and Target
finance.yahoo.com - September 25 at 8:45 AM
Expected Value Investing: Diving Deeper On ConatusExpected Value Investing: Diving Deeper On Conatus
seekingalpha.com - September 24 at 4:39 PM
Conatus Pharmaceuticals to Host Analyst and Investor Symposium on Portal HypertensionConatus Pharmaceuticals to Host Analyst and Investor Symposium on Portal Hypertension
feeds.benzinga.com - September 20 at 7:52 AM
This page was last updated on 12/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel